Results, Clinical Results from the Clinical Trial of Qilu Pharmaceutical's Novel Anticancer Agent Iparomlimab and Tuvonralimab Featured in Oral Presentation at the ESGO Annual Meeting 07.08.2025 - 18:06:04 | prnewswire.co.uk Qilu Pharmaceutical Co., Ltd. China View original content:https://www.prnewswire.co.uk/news-releases/results-from-the-clinical-trial-of-qilu-pharmaceuticals-novel-anticancer-agent-iparomlimab-and-tuvonralimab-ql1706-featured-in-oral-presentation-at-the-esgo-annual-meeting-302078257.html en | boerse | 67962363 |
